Women’s health at FDA
This article was originally published in The Gray Sheet
Executive Summary
Drug center scientist Kathleen Uhl will become director of FDA's Office of Women's Health in mid-December, the agency announces Nov. 21. Theresa Toigo has served as acting head since Sept. 16 to fill a hole left by Susan Wood, who resigned in protest over the agency's handling of Barr's Plan B emergency contraceptive pill (1"The Gray Sheet" Sept. 5, 2005, p. 6)...
You may also be interested in...
FDA Women’s Health Director Susan Wood Resigns In Protest Over Plan B
FDA Women's Health Director Susan Wood resigned Aug. 31 in protest over the agency's handling of Barr's Plan B emergency contraceptive application
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.